Relay Therapeutics (RLAY) Revenue & Revenue Breakdown
Relay Therapeutics Revenue Highlights
Latest Revenue (Y)
$10.01M
Relay Therapeutics Revenue by Period
Relay Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $10.01M | -60.83% |
2023-12-31 | $25.55M | 1749.82% |
2022-12-31 | $1.38M | -54.41% |
2021-12-31 | $3.03M | -96.34% |
2020-12-31 | $82.65M | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Relay Therapeutics generated $10.01M in revenue during NA 2024, up -60.83% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Relay Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | -100.00% |
2024-03-31 | $10.01M | -1000800.00% |
2023-12-31 | $-1.00K | -100.00% |
2023-09-30 | $25.20M | 21078.15% |
2023-06-30 | $119.00K | -47.35% |
2023-03-31 | $226.00K | -10.67% |
2022-12-31 | $253.00K | -26.45% |
2022-09-30 | $344.00K | -5.75% |
2022-06-30 | $365.00K | -12.89% |
2022-03-31 | $419.00K | -26.10% |
2021-12-31 | $567.00K | -14.86% |
2021-09-30 | $666.00K | -21.09% |
2021-06-30 | $844.00K | -11.34% |
2021-03-31 | $952.00K | -98.85% |
2020-12-31 | $82.65M | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | - |
Relay Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Relay Therapeutics Revenue Breakdown
Relay Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
Product/Service | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|
License | $300.00K | $300.00K | $200.00K |
Latest
Relay Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: License (100.00%).
Relay Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
Country | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|
License | $300.00K | $300.00K | $200.00K |
Latest
Relay Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 22: License (100.00%).
Relay Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
APLS | Apellis Pharmaceuticals | $709.95M | $176.57M |
BPMC | Blueprint Medicines | $508.82M | $128.18M |
ARVN | Arvinas | $263.40M | $102.40M |
DAWN | Day One Biopharmaceuticals | $131.16M | $20.07M |
AMLX | Amylyx Pharmaceuticals | $87.37M | $416.00K |
GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
NRIX | Nurix Therapeutics | $54.55M | $18.45M |
STOK | Stoke Therapeutics | $36.55M | $4.89M |
FHTX | Foghorn Therapeutics | $22.60M | $7.81M |
CCCC | C4 Therapeutics | $20.76M | - |
RLAY | Relay Therapeutics | $10.01M | - |
IPSC | Century Therapeutics | $6.59M | $791.00K |
CGEM | Cullinan Oncology | - | - |
BDTX | Black Diamond Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
MLYS | Mineralys Therapeutics | - | - |
TERN | Terns Pharmaceuticals | - | - |
PLRX | Pliant Therapeutics | - | - |